Enforced expression of a truncated form of Bax-α (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 99-105

  Toyota, Hiroko ^a   Kondo, Seiji ^b   Kyo, Satoru ^c   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS   (United States)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell death; Gene therapy; hTERT; tBAX

Indexed keywords

ANNEXIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; LUCIFERASE; PROTEIN BAX; PROTEIN BAX ALPHA; PROTEIN BCL XL; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENE THERAPY; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SENSITIZATION; SQUAMOUS CELL CARCINOMA; STAINING; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BONE NEOPLASMS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; ETOPOSIDE; GENE THERAPY; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; OSTEOSARCOMA; PEPTIDE FRAGMENTS; PROMOTER REGIONS (GENETICS); TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32144434429     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Fulda S and Debatin KM: Signaling through death receptors in cancer therapy. Curr Opin Pharmacol 4: 327-332, 2004.
2. Waxman DJ and Schwartz PS: Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 63: 8563-8572, 2003.
3. Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S and Dong JY: The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther 1: 123-136, 2001.
4. Bykov VJ and Wiman KG: Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med 35: 458-465, 2003.
5. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
6. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
7. Usui K, Saijo Y, Narumi K, Koyama S, Maemondo M, Kikuchi T, Tazawa R, Hagiwara K, Ishibashi Y, Ohta S and Nukiwa T: N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers. Oncogene 22: 2655-2663, 2003.
8. Toyota H, Yanase N, Yoshimoto T, Moriyama M, Sudo T and Mizuguchi J: Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett 189: 221-230, 2003.
9. Kobayashi T, Sawa H, Morikawa J, Zhang W and Shiku H: Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells. Jpn J Cancer Res 91: 1264-1268, 2000.
10. Lee A, DeJong G, Guo J, Bu X and Jia WW: Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model. Cancer Gene Ther 7: 1113-1119, 2000.
11. Arafat WO, Buchsbaum DJ, Gomez-Navarro J, Tawil SA, Olsen C, Xiang J, El-Akad H, Salama AM, Badib AO, Stackhouse MA and Curiel DT: An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int J Radiat Oncol Biol Phys 55: 1037-1050, 2003.
12. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J and Fang B: Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 9: 1379-1386, 2002.
13. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA and Fang B: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60: 5359-5364, 2000.
14. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S and Kondo S: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61: 5796-5802, 2001.
15. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS and Vasserot AP: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8: 568-578, 2001.
16. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S and Kondo S: FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 21: 1937-1943, 2001.
17. Gu J, Andreeff M, Roth JA and Fang B: hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9: 30-37, 2002.
18. Suzuki H, Hotta T, Koyama T, Komagata M, Imakiire A, Yanase N, Yoshimoto T and Mizuguchi J: Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents cooperatively induce apoptotic cell death in both sarcoma and myeloma cells. Anticancer Res 23: 3247-3253, 2003.
19. L during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncol 36: 277-285, 2000.
20. Hata K, Yoshimoto T and Mizuguchi J: CD40 ligand rescues inhibitor of differentiation 3-mediated G1 arrest induced by anti-IgM in WEHI-231 B lymphoma cells. J Immunol 173: 2453-2461, 2004.
21. Nechushtan A, Smith CL, Hsu YT and Youle RJ: Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 18: 2330-2341, 1999.
22. Chandar N, Billig B, McMaster J and Novak J: Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65: 208-214, 1992.
23. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M and Mizuguchi J: Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthopaed Res 21: 949-957, 2003.
24. Hersey P and Zhang XD: How melanoma cells evade trail-induced apoptosis. Nature Rev Cancer 1: 142-150, 2001.
25. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000.
26. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75, 1999.
27. Noutomi T, Chiba H, Itoh M, Toyota H and Mizuguchi J: Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 38: 41-48, 2002.
28. Simonian PL, Grillot DA and Nunez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216, 1997.
29. Brockstein BE and Vokes EE: Oral chemotherapy in head and neck cancer. Drugs 58 Suppl 3: 91-97, 1999.
30. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol 12: 330-336, 2000.
31. Colvin OM: Drug resistance in the treatment of sarcomas. Semin Oncol 24: 580-591, 1997.
32. Eastman A: Mechanisms of resistance to cisplatin. Cancer Treat Res 57: 233-249, 1991.
33. Susin SA, Zamzami N and Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366: 151-165, 1998.
34. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
35. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
36. Tai YT, Strobel T, Kufe D and Cannistra SA: In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 59: 2121-2126, 1999.
37. Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, Fang B, Denner L and Marcelli M: Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res 61: 186-191, 2001.
38. Lemoine NR and McNeish IA: Gene transfer: Bax to the future for cancer therapy. Gut 53: 478-479, 2004.
39. Itoh M, Noutomi T, Toyota H and Mizuguchi J: Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 39: 269-276, 2003.
40. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
41. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999.
42. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
43. Shen Y and White E: p53-dependent apoptosis pathways. Adv Cancer Res 82: 55-84, 2001.